Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Type 2 Diabetes Inadequately Controlled with Diet and Exercise (First-Line Drug Treatment) | Decision Base | US/EU | 2014
When Metformin Is Not a Therapeutic Option, What Treatments Hold Greatest Appeal to Physicians and Payers? Affecting more than 30 million people in the United States alone, type 2 diabetes is a…
Convenient Once-daily Fixed-dose Combination Inhaler and Late-Stage Emerging Biologics in Asthma: How Will U.S. Payers and Prescribers Manage Different Segments of the Asthma Market? | Physician & Payer Forum | US | 2014
Asthma is a chronic inflammatory disorder of the airways leading to recurring episodes of wheezing, breathlessness, chest tightness, and coughing, with episodes characterized by airflow obstruction…
The Impact of ACOs on Prescribing for Acute Coronary Syndrome and Atrial Fibrillation: Actionable Insights from U.S. Payers and Prescribers | Physician & Payer Forum | US | 2014
Accountable care organizations (ACOs), in which providers are held accountable for the costs of treating a payer’s patent population, will become more the rule than the exception in a year, as…
Chronic Myelogenous Leukemia: Prescribing Decisions and Payer Landscape in a Crowded and Dynamic Market | Physician & Payer Forum | EU5 | 2014
Tyrosine kinase inhibitors (TKIs) have revolutionized the management of chronic myelogenous leukemia (CML) over the last decade. However, as 2013-approved second-generation TKIs Bosulif (Pfizer’s…
MRSA Infections ( How Will U.S. Physician and Payer Receptivity to Novel Therapies Influence the Hospital-Treated Infections Market?) | Physician & Payer Forum | US | 2014
The hospital-treated methicillin-resistant Staphylococcus aureus (MRSA) infection market is dominated by generic vancomycin because of its low cost, physician familiarity and relatively high…
